Tyme Technologies Inc. (NASDAQ: TYME) has received a notification from the US Patent and Trademark Office regarding an additional patent grant in claims related to its metabolomics tech platform. Patent No. 11,058,638 involves targeted therapeutics delivery to cancer cells.
Tyme receives a patent for its metabolomics tech platform
The company has discovered a technique that allows the tyrosine isomer racemetyrosine to be fused with another therapeutic drug to form a fusion product that may allow for innovative cancer cell targeting. This administration technique is based on a metabolic process in which cancer cells absorb more non-essential amino acids, such as tyrosine, from their surroundings to sustain their growth since they cannot produce enough amino acids.
Tyme CEO Richie Cunningham said, “This delivery technology is another example of our innovative spirit at Tyme. Even though this approach is still in its early stages, if proven, it has the potential to be a broadly leveraged platform technology.”
Steve Hoffman, the company’s chief scientific officer, added, “This technology could provide Tyme an opportunity to expand its current cancer-metabolism based approach with a drug delivery platform that’s aimed to deliver toxic therapies in a targeted manner that could offer improved safety and efficacy for a range of anticancer drugs.”
Delivery technique yet to receive approval in the US
The delivery technique is a pre-clinical experimental method of drug delivery that is yet to be approved in the United States for any medical indication. It requires additional research, which Tyme hopes to begin this year.
The company develops cancer metabolism-based therapies that are likely to be effective in various tumor types. Notably, unlike targeted therapies attempting to regulate specific mutations in cancer, Tyme’s therapeutic approach takes advantage of the innate metabolism weakness of tumor cells to compromise defenses resulting in death via oxidative stress and contact with the body’s natural immune system.